multiple sclerosis

Looking to cement its lead in packed MS market, Roche's Ocrevus uncorks new data in early-stage patients
Looking to cement its lead in packed MS market, Roche's Ocrevus uncorks new data in early-stage patients
Endpoints
Roche
Ocrevus
MS
multiple sclerosis
clinical trials
Flag link:
Here's a Multibillion-Dollar Market for Johnson & Johnson
Here's a Multibillion-Dollar Market for Johnson & Johnson
Motley Fool
JNJ
Ponvory
MS
multiple sclerosis
Flag link:
Helius Medical’s device gets FDA all clear to stimulate the brain via the tongue
Helius Medical’s device gets FDA all clear to stimulate the brain via the tongue
MedCity News
Helius
devices
FDA
brain stimulation
multiple sclerosis
MS
Flag link:
BrainStorm Trial Shows Promising Top-Line Results for Progressive Multiple Sclerosis
BrainStorm Trial Shows Promising Top-Line Results for Progressive Multiple Sclerosis
BioSpace
BrainStorm Cell Therapeutics
MS
clinical trials
multiple sclerosis
Flag link:
J&J nabs FDA nod for Ponvory, joining Novartis, Bristol Myers in crowded MS market
J&J nabs FDA nod for Ponvory, joining Novartis, Bristol Myers in crowded MS market
Fierce Pharma
JNJ
Ponvory
Novartis
Bristol-Myers Squibb
MS
multiple sclerosis
Flag link:
Bristol Myers Squibb's MS innovation challenge winners tap technology for patients
Bristol Myers Squibb's MS innovation challenge winners tap technology for patients
Fierce Pharma
Bristol-Myers Squibb
innovation
MS
multiple sclerosis
devices
Evolution Devices
aritificial intelligence
Flag link:
Novartis sues FDA over its stance on Sanofi blockbuster’s exclusivity
Novartis sues FDA over its stance on Sanofi blockbuster’s exclusivity
Endpoints
Novartis
generics
Sandoz
FDA
Aubagio
multiple sclerosis
MS
Flag link:
Novartis study: Nurses and MS patients give thumbs-up to Kesimpta for ease of use
Novartis study: Nurses and MS patients give thumbs-up to Kesimpta for ease of use
Fierce Pharma
Novartis
Kesimpta
MS
multiple sclerosis
Flag link:
MS study points to the gut microbiome as a potential source of the disease
MS study points to the gut microbiome as a potential source of the disease
Fierce Biotech
MS
multiple sclerosis
microbiome
IL-17
Flag link:
Biogen to pay $22 million to resolve U.S. drug charity kickback probe
Biogen to pay $22 million to resolve U.S. drug charity kickback probe
Reuters
Biogen
MS
kickbacks
Medicare
multiple sclerosis
Flag link:
Roche's MS blockbuster Ocrevus, facing new Novartis competition, scores FDA nod for more-convenient infusion
Roche's MS blockbuster Ocrevus, facing new Novartis competition, scores FDA nod for more-convenient infusion
Fierce Pharma
Roche
Novartis
Kesimpta
Ocrevus
MS
multiple sclerosis
Flag link:
TG adds a multiple sclerosis string to its bow
TG adds a multiple sclerosis string to its bow
EP Vantage
TG Therapeutics
hematology
ASH2020
ublituximab
MS
multiple sclerosis
Flag link:
MediciNova's Ibudilast Reduces Retinal Thinning in MS Trial Subjects
MediciNova's Ibudilast Reduces Retinal Thinning in MS Trial Subjects
BioSpace
MediciNova
OCT
clinical trials
ibudilast
MS
multiple sclerosis
retinal thinning
Flag link:
GW Pharma Hopes to Bring Its Second Cannabis-Based Drug to Market in the U.S.
GW Pharma Hopes to Bring Its Second Cannabis-Based Drug to Market in the U.S.
BioSpace
GW Pharma
cannabindoids
multiple sclerosis
spasticity
nabiximols
Sativex
Flag link:
Anokion announces FDA clearance of IND application for ANK-700 to treat multiple sclerosis
Anokion announces FDA clearance of IND application for ANK-700 to treat multiple sclerosis
Pharmaceutical Business Review
Anokion
ANK-700
multiple sclerosis
Flag link:
Novartis set to take on Roche as FDA clears first at-home, injectable MS drug
Novartis set to take on Roche as FDA clears first at-home, injectable MS drug
Biopharma Dive
Novartis
FDA
Kesimpta
ofatumumab
MS
multiple sclerosis
Flag link:
Teva shares slide as it faces illegal kickback charges from US government
Teva shares slide as it faces illegal kickback charges from US government
Pharmaforum
Teva Pharmaceutical
kickbacks
DOJ
Copaxone
MS
multiple sclerosis
Flag link:
Mylan launches first generic to Tecfidera in multiple sclerosis
Mylan launches first generic to Tecfidera in multiple sclerosis
Seeking Alpha
Mylan
generics
Tecfidera
Biogen
MS
multiple sclerosis
Flag link:
U.S. court upholds patent for Novartis MS drug Gilenya
U.S. court upholds patent for Novartis MS drug Gilenya
Reuters
Novartis
patents
Gilenya
MS
multiple sclerosis
Flag link:
Sanofi, seeking control of key drug, to buy Principia for $3.7B
Sanofi, seeking control of key drug, to buy Principia for $3.7B
BioPharma Dive
Sanofi
Principia Biopharma
M&A
multiple sclerosis
MS
SAR442168
Flag link:

Pages